SCHEMBL4556562

SCHEMBL4556562

Oc1ccc2c(c1-c1ccccc1)OCO2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.49
HSP90AB1 P08238 5/20 0.49
AOC3 Q16853 1/20 0.45
CYP1A2 P05177 2/20 0.42
CYP1B1 Q16678 2/20 0.42
CYP1A1 P04798 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.40
PTGS2 P35354 2/20 0.38
KDM4C Q9H3R0 1/20 0.38
CYP3A4 P08684 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
MEN1 O00255 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12023132 0.85 AOC3 (0.53) HSP90AA1HSP90AB1AOC3ABCG2KDM4C
SCHEMBL29240259 0.81 HSP90AA1 (0.44) HSP90AA1HSP90AB1AOC3CYP1A2CYP1B1
SCHEMBL14302835 0.78 CYP1A2 (0.51) CYP1A2CYP1B1CYP1A1ABCG2PTGS2
SCHEMBL12023063 0.78 AOC3 (0.47) HSP90AA1HSP90AB1AOC3KDM4CCYP3A4
SCHEMBL14950291 0.77 AOC3 (0.44) HSP90AA1HSP90AB1AOC3ABCG2KDM4C
SCHEMBL9036919 0.77 CYP1A2 (0.39) HSP90AA1HSP90AB1CYP1A2CYP1B1CYP1A1
SCHEMBL9695924 0.76 NPC1 (0.42) AOC3CYP1A2CYP1B1CYP1A1PTGS2
SCHEMBL27033249 0.72 AOC3 (0.53) HSP90AA1HSP90AB1AOC3ABCG2KDM4C
SCHEMBL9788822 0.72 HPGD (0.41) CYP1A2CYP1B1CYP1A1NPC1RAB9A
SCHEMBL13695077 0.71 AOC3 (0.37) HSP90AA1HSP90AB1AOC3CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1436191-B Antitumor ecteinascidin derivatives PHARMA MAR SA 2011-09-14 CN disclosed
US-20090156635-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS GILLESPIE PAUL 2009-06-18 US disclosed
US-7524870-B2 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators HOFFMANN-LA ROCHE INC. (US) 2009-04-28 US disclosed
CN-100475822-C Synthesis method for producing ecteinascidin compound PHARMA MAR SA (ES) 2009-04-08 CN disclosed
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GILLESPIE PAUL 2006-06-08 US disclosed
CN-1211386-C Antitumoral analogue of Et-743 PHARMA MAR SA (ES) 2005-07-20 CN disclosed
CN-1441805-A Antitumoral analogue of Et-743 PHARMA MAR SA (ES) 2003-09-10 CN disclosed
CN-1440414-A synthetic method for producing ecteinascidin compounds PHARMA MAR SA (ES) 2003-09-03 CN disclosed
CN-1436193-A Antitumoral ecteinascidin derivs PHARMA MAR SA (ES) 2003-08-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156635-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS GYS2, GYS1, GSK3A HSP90AA1 2641/4885HSP90AB1 2761/4885AOC3 2598/4885
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GYS2, GYS1, GSK3A HSP90AA1 2641/4885HSP90AB1 2761/4885AOC3 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.